The PARADIGM trial is set to evaluate the diagnostic performance of artificial intelligence (AI) compared to radiologists in detecting clinically significant prostate cancer. Supported by various healthcare organizations, the study will recruit 500 men over 18 months, employing standard MRI procedures. The trial will report on the proportion of men with significant cancer and assess the performance characteristics of both AI and radiologists. With a notable increase in prostate cancer incidence projected, this trial aims to address the rising demand for MRI screening amidst a potential shortage of radiologists. Recruitment for PARADIGM is expected to begin in October 2026.
Fri, 17 Apr 2026 06:56:16 GMT | European Medical Journal